[go: up one dir, main page]

EA201691521A1 - Антитела к интерлейкину-21 - Google Patents

Антитела к интерлейкину-21

Info

Publication number
EA201691521A1
EA201691521A1 EA201691521A EA201691521A EA201691521A1 EA 201691521 A1 EA201691521 A1 EA 201691521A1 EA 201691521 A EA201691521 A EA 201691521A EA 201691521 A EA201691521 A EA 201691521A EA 201691521 A1 EA201691521 A1 EA 201691521A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
methods
interleukin
warranted
autoimmune
Prior art date
Application number
EA201691521A
Other languages
English (en)
Other versions
EA033335B1 (ru
Inventor
Джулиан Дэвис
Фабио МАГРИНИ
Андреа Паула Мартин
Неелуфар Мозаффариан
Четанкумар Натварлал Пател
Оливер Шрёдер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201691521A1 publication Critical patent/EA201691521A1/ru
Publication of EA033335B1 publication Critical patent/EA033335B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к сконструированным, гуманизированным антителам, которые обладают высокой аффинностью связывания и нейтрализуют ИЛ-21 человека, к способам применения указанных антител для лечения состояний, в которых оправданным является антагонистическое воздействие на ИЛ-21 или нейтрализация активности ИЛ-21, таких как аутоиммунные состояния, к композициям и способам получения указанных антител с помощью рекомбинантных методик и фармацевтическим композициям, содержащим указанные антитела.
EA201691521A 2014-03-21 2015-03-13 Антитело к интерлейкину-21 и его применение для лечения аутоиммунного состояния EA033335B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21
PCT/US2015/020383 WO2015142637A1 (en) 2014-03-21 2015-03-13 Il-21 antibodies

Publications (2)

Publication Number Publication Date
EA201691521A1 true EA201691521A1 (ru) 2017-02-28
EA033335B1 EA033335B1 (ru) 2019-09-30

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691521A EA033335B1 (ru) 2014-03-21 2015-03-13 Антитело к интерлейкину-21 и его применение для лечения аутоиммунного состояния

Country Status (24)

Country Link
US (1) US9394362B2 (ru)
EP (1) EP3119806B1 (ru)
JP (2) JP6053989B2 (ru)
KR (1) KR101859857B1 (ru)
CN (1) CN106061999B (ru)
AP (1) AP2016009450A0 (ru)
AR (1) AR099625A1 (ru)
AU (1) AU2015231777B2 (ru)
BR (1) BR112016019176A2 (ru)
CA (1) CA2939543C (ru)
CL (1) CL2016002281A1 (ru)
EA (1) EA033335B1 (ru)
EC (1) ECSP16075416A (ru)
ES (1) ES2774422T3 (ru)
IL (1) IL246909A0 (ru)
MA (1) MA39342B2 (ru)
MX (1) MX2016012120A (ru)
MY (1) MY177915A (ru)
NZ (1) NZ722518A (ru)
PE (1) PE20161221A1 (ru)
PH (1) PH12016501820A1 (ru)
SG (1) SG11201606705QA (ru)
TW (1) TWI646105B (ru)
WO (1) WO2015142637A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3128997B1 (en) 2014-04-08 2020-08-05 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
JP2018536650A (ja) * 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
WO2017172509A1 (en) * 2016-03-31 2017-10-05 Eli Lilly And Company Il-21 antibodies and uses thereof
BR112020022892A2 (pt) * 2018-05-31 2021-02-23 Glycom A/S mistura de hmos para tratamento de doenças autoi-munes
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
EP4017594A1 (en) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
KR20240035825A (ko) 2021-07-09 2024-03-18 다인 세라퓨틱스, 인크. 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2024525611A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用
KR20240035824A (ko) * 2021-07-09 2024-03-18 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275221B (zh) * 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
KR20050119120A (ko) 2003-03-14 2005-12-20 와이어쓰 인간 ⅰｌ-21 수용체에 대한 항체 및 그것의 용도
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
EP2567973B1 (en) * 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists
US7592427B2 (en) * 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
BRPI0820099A2 (pt) * 2007-12-07 2020-11-24 Zymogenetics, Inc anticorpo isolado ou fragmento de anticorpo, composição farmacêutica, e, uso de um anticorpo ou fragmento de anticorpo
CN102027011B (zh) * 2007-12-07 2014-09-03 津莫吉尼蒂克斯公司 抗人il-21单克隆抗体
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
EP2714198A1 (en) * 2011-05-31 2014-04-09 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Also Published As

Publication number Publication date
EA033335B1 (ru) 2019-09-30
JP6053989B2 (ja) 2017-01-11
NZ722518A (en) 2017-12-22
JP6373944B2 (ja) 2018-08-15
AU2015231777A1 (en) 2016-08-18
US20150266954A1 (en) 2015-09-24
TW201623330A (zh) 2016-07-01
CN106061999B (zh) 2020-07-31
IL246909A0 (en) 2016-09-29
MY177915A (en) 2020-09-25
AP2016009450A0 (en) 2016-09-30
MA39342A1 (fr) 2018-03-30
BR112016019176A2 (pt) 2017-10-10
CL2016002281A1 (es) 2017-06-23
MX2016012120A (es) 2016-12-09
EP3119806A1 (en) 2017-01-25
AU2015231777B2 (en) 2017-08-03
KR101859857B1 (ko) 2018-05-18
AR099625A1 (es) 2016-08-03
ES2774422T3 (es) 2020-07-21
KR20160124166A (ko) 2016-10-26
US9394362B2 (en) 2016-07-19
ECSP16075416A (es) 2018-05-31
CA2939543A1 (en) 2015-09-24
MA39342B2 (fr) 2020-03-31
TWI646105B (zh) 2019-01-01
PE20161221A1 (es) 2016-11-12
JP2016520088A (ja) 2016-07-11
JP2017093435A (ja) 2017-06-01
CA2939543C (en) 2018-01-16
WO2015142637A1 (en) 2015-09-24
CN106061999A (zh) 2016-10-26
PH12016501820A1 (en) 2016-11-07
SG11201606705QA (en) 2016-09-29
EP3119806B1 (en) 2020-01-01
EP3119806A4 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
EA201691521A1 (ru) Антитела к интерлейкину-21
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
ZA201708265B (en) Tigit-binding agents and uses thereof
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
MX2019005426A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
PH12017501522B1 (en) Antibodies to tau and uses thereof
EA201791485A1 (ru) Анти-cd47-антитела и их применения
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
GEP201706794B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
PH12016502535B1 (en) Interferon alpha and omega antibody antagonists
EA201890434A1 (ru) Антитела к cd154 и способы их применения
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX390653B (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU